This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) is currently focusing on improving clinical quality.
Zacks.com featured expert Kevin Matras highlights: Robert Half International, Caseys General Stores, Amedisys, Foot Locker and Comfort Systems USA
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Robert Half International, Caseys General Stores, Amedisys, Foot Locker and Comfort Systems USA
Believe in DuPont Analysis? Tap These 5 Top-Ranked Stocks
by Sanghamitra Saha
DuPont technique helps investors to analyze basic ROE at an advanced level. Bet on these five stocks.
These 5 Low Leverage Stocks Are Safe Bets
by Zacks Equity Research
The crux of safe investment is to choose stocks that bear low debt-to-equity ratios, yet have notable earnings surprise history.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q4
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains from growth in Medicare and non-Medicare revenues in Q4.
Zacks.com featured expert Kevin Matras highlights: Robert Half International, Caseys General Stores, Amedisys, Foot Locker and Comfort Systems USA
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Robert Half International, Caseys General Stores, Amedisys, Foot Locker and Comfort Systems USA
Quest Diagnostics Grows on Innovation Amid Reimbursement Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
Zacks.com featured highlights include: Merit Medical, Pinnacle West, Amedysis, Southwest Airlines and Royal Caribbean
by Zacks Equity Research
Zacks.com featured highlights include: Merit Medical, Pinnacle West, Amedysis, Southwest Airlines and Royal Caribbean
Have Faith in DuPont Analysis & Pick 5 Quality Stocks
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived the DuPont way.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Worried About Rate Hikes? Buy These 5 Low Leverage Stocks
by Zacks Equity Research
If a company is highly leveraged, investors will not add it to their portfolios. A high degree of financial leverage means high interest payments, which may affect a company's bottom line.
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
by Zacks Equity Research
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
by Zacks Equity Research
The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.
Align Technology Unveils iTero Element 5D Imaging System
by Zacks Equity Research
Align Technology (ALGN) continues to expand work flow options of iTero scanners.
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
by Zacks Equity Research
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
Boston Scientific Benefits From New Buyouts & Product Launch
by Zacks Equity Research
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
by Zacks Equity Research
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.
Amedisys (AMED) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Investment Tips to Help You Achieve Your 2019 Goals
by Chandrima Sanyal
Here are a few ways to invest your money that will help you improve your financial health and mitigate the impacts of any potential adversity.
Amedisys (AMED) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amedisys (AMED) closed the most recent trading day at $129.41, moving +1.47% from the previous trading session.
Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.
ADUS vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ADUS vs. AMED: Which Stock Is the Better Value Option?